Ata Ppgl Chemotherapy Indication

---
name: ata-ppgl-chemotherapy-indication
description: Recommends CVD chemotherapy as first-line systemic treatment for unresectable pheochromocytoma/paraganglioma with rapid progression or when radionuclide therapy is not applicable. Considers disease progression rate and feasibility to choose between CVD chemotherapy and radionuclide therapy in patients with positive nuclear imaging when progression is slow and radionuclide therapy feasible.
---

# Indicate chemotherapy for unresectable pheochromocytoma and paraganglioma

## STEP 1 — Gather Information
Collect: unresectability status (surgical/technical), progression rate (rapid vs slow based on tumor growth or biomarker rise), nuclear imaging results (123I-MIBG scintigraphy, somatostatin receptor PET/CT), feasibility of radionuclide therapy (availability, contraindications), baseline labs (CBC, LFT, renal function), catecholamine levels, symptoms, ECOG performance status.  
**Action:** Proceed to assess resectability.

## STEP 2 — Rule In / Rule Out
Is the PPGL unresectable (locally advanced, metastatic, or medically inoperable)?  
- If **resectable** → recommend surgical resection (not chemotherapy).  
- If **unresectable** → proceed to evaluate progression rate and radionuclide feasibility.  

## STEP 3 — Classify or Stratify
Is disease progression rapid **or** is radionuclide therapy not applicable (contraindicated, unavailable, or patient refuses)?  
- If **yes** → recommend CVD chemotherapy as first-line systemic treatment.  
- If **no** (slow progression and radionuclide therapy feasible) → proceed to assess nuclear imaging status.  

## STEP 4 — Decide
Based on nuclear imaging:  
- If **positive** (123I-MIBG or somatostatin receptor avid uptake) → choose between CVD chemotherapy and radionuclide therapy: favor CVD chemotherapy if progression is rapid or radionuclide feasibility low; favor radionuclide therapy if progression is slow and therapy feasible.  
- If **negative** → recommend CVD chemotherapy (preferred when nuclear imaging negative).  
**Action:** Initiate selected systemic therapy with appropriate pretreatment (α‑blockade, hydration) and monitoring.  

## Clinical Guardrails / Mimics / Pitfalls
Do not use CVD chemotherapy in patients with severe bone marrow suppression (ANC <1.0×10⁹/L, platelets <50×10⁹/L), uncontrolled hypertension despite adequate α‑blockade, active infection, or pregnancy. Avoid in patients with severe hepatic or renal dysfunction (ALT/AST >3×ULN, creatinine clearance <30 mL/min). Monitor for hypertensive crisis due to tumor lysis during early cycles; have phentolamine ready. Do not substitute CVD chemotherapy for observation in indolent disease without progression.  

## Concrete Clinical Example
A 60‑year‑old with unresectable retroperitoneal PPGL, rising normetanephrine (×3 ULN in 3 months), lung metastases, 123I‑MBG scintigraphy negative, ECOG 1, normal CBC and LFTs. Disease deemed rapidly progressive; radionuclide therapy not considered due to negative imaging.  
**Action:** Start CVD chemotherapy (cyclophosphamide 750 mg/m² day 1, vincristine 1.4 mg/m² day 1, dacarbazine 600 mg/m² days 1‑2) every 21 days.  

**Source:** Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, doi:10.1507/endocrj.EJ25-0165